Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Adult Hodgkin lymphoma AND MYC, c-Myc, 4609, ENSG00000136997 AND Clinical Outcome
10 results:

  • 1. Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma.
    Youssef Y; Karkhanis V; Chan WK; Jeney F; Canella A; Zhang X; Sloan S; Prouty A; Helmig-Mason J; Tsyba L; Hanel W; Zheng X; Zhang P; Chung JH; Lucas DM; Kauffman Z; Larkin K; Strohecker AM; Ozer HG; Lapalombella R; Zhou H; Xu-Monette ZY; Young KH; Han R; Nurmemmedov E; Nuovo G; Maddocks K; Byrd JC; Baiocchi RA; Alinari L
    Haematologica; 2021 Nov; 106(11):2927-2939. PubMed ID: 33054136
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-myc, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. C-myc and BCL2 translocation frequency in diffuse large B-cell lymphomas: A study of 97 patients.
    Akkaya B; Salim O; Akkaya H; Ozcan M; Yucel OK; Erdem R; Iltar U; Undar L
    Indian J Pathol Microbiol; 2016; 59(1):41-6. PubMed ID: 26960633
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Upregulation of miRNA-17 and miRNA-19 is associated with unfavorable prognosis in patients with T-cell lymphoblastic lymphoma.
    Xi Y; Li J; Zhang P; Bai W; Gao N; Bai W; Zhang Y; Wu Y; Ning Y
    Exp Mol Pathol; 2015 Oct; 99(2):297-302. PubMed ID: 26231295
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Glycolytic inhibitor 2-deoxy-d-glucose suppresses cell proliferation and enhances methylprednisolone sensitivity in non-hodgkin lymphoma cells through down-regulation of HIF-1α and c-myc.
    Pang YY; Wang T; Chen FY; Wu YL; Shao X; Xiao F; Huang HH; Zhong H; Zhong JH
    Leuk Lymphoma; 2015 Jun; 56(6):1821-30. PubMed ID: 25219592
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.
    Bellas C; García D; Vicente Y; Kilany L; Abraira V; Navarro B; Provencio M; Martín P
    PLoS One; 2014; 9(6):e98169. PubMed ID: 24887414
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. BCL2, BCL6, myc, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
    Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
    Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion.
    Vakiani E; Nandula SV; Subramaniyam S; Keller CE; Alobeid B; Murty VV; Bhagat G
    Hum Pathol; 2007 Feb; 38(2):315-25. PubMed ID: 17134734
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. p53 mutations, c-myc and bcl-2 rearrangements in human non-hodgkin's lymphoma cell lines.
    Chang H; Blondal JA; Benchimol S; Minden MD; Messner HA
    Leuk Lymphoma; 1995 Sep; 19(1-2):165-71. PubMed ID: 8574164
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-hodgkin's lymphoma: identification of a subgroup with favorable clinical outcome.
    Kaplan LD; Shiramizu B; Herndier B; Hahn J; Meeker TC; Ng V; Volberding PA; McGrath MS
    Blood; 1995 Apr; 85(7):1727-35. PubMed ID: 7535586
    [TBL] [Abstract] [Full Text] [Related]  

    of 1.